An early study demonstrated that co-targeted PI3K and MEK signaling pathways enhanced cytotoxicity of histone deacetylase inhibitors in NSCLC and chronic myeloid leukemia[35]. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.